TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00909545
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 Placebo to Match (PTM) tablets once daily
Study: NCT04129788
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: three doses taken, one per day on three consecutive days
Study: NCT02076828
Drug: Ferro Sanol® sp
Approvals — FDA: no, EMA: no, PMDA: no
Description: The children with IDA that included in Fe-S (Ferro Sanol® sp.)(Group I) were treated with a therapeutic dose Ferro Sanol® sp as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
Study: NCT02076828
Drug: Santafer® sp.
Approvals — FDA: no, EMA: no, PMDA: no
Description: The children with IDA that included in Fe-OH-PM (Santafer® sp.)(Group II) were treated with a therapeutic dose Santafer® as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
Study: NCT02076828
Drug: Ferro Zinc® sp
Approvals — FDA: no, EMA: no, PMDA: no
Description: The children with IDA that included in Fe-Zn (Ferro Zinc® sp.)(Group III) were treated with a therapeutic dose Ferro Zinc® sp. as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
Study: NCT04564612
Drug: BIIB091
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT01218100
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, oral administration/QD/oral administration/up to 12 weeks Placebo capsule, oral administration/QD/oral administration/up to 12 weeks
Study: NCT02093429
Drug: INCB047986
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB047986 will be supplied as tablets.
Study: NCT04059523
Drug: S6G5T-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT04059523
Drug: Retin-A® 0.1% Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT02952963
Drug: Chenodeoxycholic Acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02178813
Drug: Administration of minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of minocycline with the following schedule:~* Day prior to procedure: 800mg p.o., 700mg p.o.~* Day of procedure: 600mg i.v., 500mg p.o.~* Day after procedure: 400mg p.o., 400mg p.o.
Study: NCT00444704
Drug: PRA-027
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00904618
Drug: Local anesthesia (30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia consisted of 30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%. Sedation was used in association with local anesthesia, including 1 mg of lorazepam sublingual as well as a combination of 0.5 to 2 mg intravenous (IV) of midazolam and 50 to 200 ug IV of fentanyl. Postoperative analgesia consisted of a prescription of 30 tablets of morphine 5 mg.
Study: NCT00413920
Drug: Enteric-coated mycophenolate sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An initial dose of 1080 mg EC-MPS was administered immediately before transplantation. Then, during the first 6 weeks post-transplantation, EC-MPS was administered at a dose of 1080 mg twice a day 12 hours apart. From week 7 until the end of the study (month 6), EC-MPS was administered at standard dose of 720 mg twice a day.
Study: NCT01244581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mixture in two daily doses for 7 days
Study: NCT03663374
Drug: Odelepan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, 125 mg
Study: NCT03663374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contains the same excipients as Odelepran but it does not contain the active agent. Placebo is identical to Odelepran in terms of drug form and external characteristics (colour, smell, etc). Doses and route of administration are identical to those for Odelepran.
Study: NCT05058105
Drug: FL058 1000mg（ IV 120min）
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1 qd;
Study: NCT05058105
Drug: FL058 Placebo （ IV 120min）
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1 qd;
Study: NCT01185964
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 75 mg/m2 by intravenous injection on day 1 of the 21-day cycle.
Study: NCT04897919
Drug: Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet
Normalized name: artemether-lumefantrine 20 mg-120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-Lumefantrine is given as recommended by manufacturer
Study: NCT00244348
Drug: 5 Fluorouracil (systemic)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00505037
Drug: ASP1585
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00505037
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04465877
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching in appearance to the active drug tablets
Study: NCT04093765
Drug: Antimalarials
Normalized name: ANTIMALARIALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: A safe, recommended treatment of P. falciparum malaria will be administered to URDT positive individuals based on participant's characteristics:~* The standard regimen for participants without known antimalarial allergy, not pregnant and not breastfeeding, will be a 3-day supervised weight-adjusted DP course and a single low dose PMQ. The single low dose PMQ will be administered on the first day.~* Pregnant women and in their 2nd or 3rd trimester, and breastfeeding mothers, will receive a DP course but no PMQ.~* Pregnant women in their first trimester will receive an oral course of quinine+clindamycin (7 days).~* Individuals with known drug allergy to piperaquine will be treated with AL (+/- sld PMQ as per their pregnancy/breastfeeding status)~* Specific/complex cases will be assessed by a medic and referred to a health facility for treatment if necessary.
Study: NCT03958656
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
Study: NCT03792672
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-653 placebo-matching tablets.
Study: NCT04119622
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: apecitabine 1000 mg/m2 BID, d1-d14 ,q3w, up to two cycles
Study: NCT02059759
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this arm will receive sub-cutaneous injections of placebo (same vehicle as for experimental arms, and same volume) for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
Study: NCT02059759
Drug: 1.0 MIU IL-2 per day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this arm will receive sub-cutaneous injections corresponding to 1.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
Study: NCT02059759
Drug: 2.0 MIU IL-2 per day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this arm will receive sub-cutaneous injections corresponding to 2.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
Study: NCT00685646
Drug: antiandrogen therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 24 courses of therapy
Study: NCT00685646
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Up to 24 courses of therapy
Study: NCT02069730
Drug: FGFR Inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with FGFR Inhibitor
Study: NCT02069730
Drug: Anti-androgen
Normalized name: Anti-androgens
Approvals — FDA: no, EMA: no, PMDA: no
Description: If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with Anti-androgens
Study: NCT02069730
Drug: NOTCH Inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with NOTCH Inhibitor
Study: NCT01564095
Drug: HTK/Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marginal liver grafts are flushed with 1000 ml HTK preservation solution(duration: 15 min) ex vivo at the end of backtable preparation in the placebo group.
Study: NCT02024022
Drug: Standard approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: bowel cleansing with either 4L PEG or sodium picosulphate/magnesium citrate
Study: NCT00420810
Drug: MK0928 / Duration of Treatment : 8 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03190265
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m2) will be administered IV on day 1 of Cycles 1 and 2.
Study: NCT03311672
Drug: [18F]F-Ara-G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered after two cycles of immunotherapy +/- stereotactic radiation therapy as part of the PET/CT scan.
Study: NCT02927366
Drug: Placebo Matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to QCC374:~0.03 mg BID, 0.06 mg BID and 0.12 mg BID
Study: NCT00747344
Drug: Placebo - Controlled Period (CP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, Weeks 0-12
Study: NCT00765882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
Study: NCT02562651
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline bid for the first 7 days after primary anterior STEMI
Study: NCT01430507
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo in triple dummy format, Tablet, Once daily for 12 weeks
Study: NCT03249935
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 1 gm PO single dose given as directly observed
Study: NCT02059850
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02747342
Drug: SHR3680; SHR3162
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR3680 will be administered orally in dose escalation/expansion phase,~SHR3680 will be administered orally at a fixed dose together with SHR3162 in combination phase.
Study: NCT03257163
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03638869
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02818036
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02181101
Drug: FEC-DocGemzar adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02181101
Drug: FEC-Doc adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02181101
Drug: Zoledronic acid i.v. 2 years
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02181101
Drug: Zoledronic acid i.v. 5 years
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00869050
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1500 mg/m2/day (PO divided BID) with a maximum daily dose of 2500mg Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle.
Study: NCT01711229
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofirmev will be given 15 minutes prior to going to the OR
Study: NCT01711229
Drug: oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral acetaminophen will be given preoperatively
Study: NCT00610441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01173029
Drug: Anti-hypertensive drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hypertensive drug treatment was non-investigational. Drug regimen, including which drug and the number of drugs prescribed, was left at discretion of the physician who carried primary assistance.
Study: NCT02388594
Drug: ZFN Modified CD4+ T Cells
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02388594
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01869361
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drug
Study: NCT01869361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control drug
Study: NCT00042068
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00777179
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00787787
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04671082
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TID
Study: NCT00554398
Drug: MK-0518 400mg twice a day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir, MK-0518
Study: NCT01445522
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04492709
Drug: AZD5718
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive oral AZD5718 tablet once daily starting on Day 2 to Day 6 in Treatment Period 2 and on Day 7 co-administered with midazolam in Treatment Period 3.
Study: NCT02696499
Drug: PA101B
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg PA101B administered via inhalation twice daily for 7 weeks
Study: NCT02696499
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered via inhalation twice daily for 7 weeks
Study: NCT02256267
Drug: LY2835219
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01386541
Drug: BYK324677
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules, administered orally
Study: NCT01587638
Drug: cardio selective betablocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol, metoprolol succinate, and metoprolol tartrate
Study: NCT03093389
Drug: BIA 6-512
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 100 mg and 150 mg. Products were administered orally, with approximately 240 mL of water in case of Doses 1 and 13, and at least 150 mL of water in case of Doses 2 to 12. First dose (Dose 1) and last dose (Dose 13) were administered in fasting of at least 8 hours and subject remained fasted until to 2.5 h post-dose. Meals were not served within 1 hour prior and 1 hour after investigational product administration in Doses 2 to 12
Study: NCT03093389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules
Study: NCT03359057
Drug: ethinyl estradiol + levonorgestrel + folic acid
Normalized name: estradiol / ethinyl estradiol / levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: One coated tablet of ethinyl estradiol + levonorgestrel + folic acid, 0.02 mg + 0.10 mg + 0.4 mg for 21 days in 3 cycles (12 weeks).
Study: NCT03359057
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One coated tablet of folic acid 0.4 mg for 7 days in 3 cycles (12 weeks).
Study: NCT04573426
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000mg liquid acetaminophen
Study: NCT04573426
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid placebo solution
Study: NCT00493636
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
Study: NCT00493636
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine).
Study: NCT02282371
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01741532
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A deferiprone matching placebo oral solution will be given twice daily for 18 months.
Study: NCT02741570
Drug: Fluorouracil/Adrucil
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01151605
Drug: insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: insulin to be infused at 3.5 units/hour along with Dextrose 12.5% at a rate to achieve blood glucose levels between 80-120mg/dl
Study: NCT01151605
Drug: Saline Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline will be infused at 100ml/hr
Study: NCT03453255
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: chidamide, decitabine, homoharringtonine, cytarabine
Study: NCT00932620
Drug: SIMVASTATIN 40 mg
Normalized name: simvastatin 40 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SIMVASTATIN 40 mg/day for 3 months
Study: NCT00932620
Drug: SIMVASTATIN/EZETIMIBE 10/10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIMVASTATIN/EZETIMIBE 10/10 mg/day for 3 months
Study: NCT01845584
Drug: NPB-01
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02370537
Drug: Epanova® (omega-3 carboxylic acids)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g (administered orally as 4 x 1 g capsules)
Study: NCT02370537
Drug: Omacor® (omega-3-acid ethyl esters)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g (administered orally as 4 x 1 g capsules)
Study: NCT00303446
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT00979368
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension, Oral, 0 mg, Once on Day 1 only, 4 days
Study: NCT01777555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03415698
Drug: Standard Medical Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics.
Study: NCT00689000
Drug: CHR-2797 (tosedostat): Aminopeptidase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: Once daily, oral ingestion of CHR-2797 capsules (60mg, 90mg, 130mg or 180mg) depending on cohort~Phase II: Once daily, oral ingestion of 130mg CHR-2797 (recommended dose from Phase I) until progressive disease or withdrawal from the study
Study: NCT00593853
Drug: Matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
Study: NCT00004446
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02068846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.
Study: NCT02093988
Drug: Topical TXA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02093988
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04205851
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT03411252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic Mirabegron
Study: NCT01967823
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenously (IV) in 250 mL dextrose 5% in water (D5W) infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
Study: NCT03690739
Drug: PLD
Normalized name: PLD1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration according to investigator's discretion
Study: NCT03690739
Drug: PLD
Normalized name: PLD1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration 30 mg/m² q21
Study: NCT01332188
Drug: AC-170 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in each eye at 3 separate times during a 21 day period
Study: NCT01332188
Drug: AC-170 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in each eye at 3 separate times during a 21 day period
Study: NCT01332188
Drug: AC-170 0.24%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in each eye at 3 separate times during a 21 day period
Study: NCT01332188
Drug: AC-170 0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in each eye at 3 separate times during a 21 day period
Study: NCT01364805
Drug: Intravenous Vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first 5 study visits will all take place in the General Clinical Research Center (GCRC). During these visits you will receive IV doses of Vitamin C. The dose of Vitamin C will be started at 25 grams and may be increased up to 125 grams over a two week period. There may be changes in the amount of Vitamin C that you receive based on your blood test levels. The study staff will go over this in more detail with you. The amount of fluid you receive depends on the dose and can be from 2 1/3 cups to 5 cups.
Study: NCT00951522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled placebo in sterile saline
Study: NCT00827281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dosage prior to sessions 3, 4 \& 5